tradingkey.logo

Evoke Pharma Inc

EVOK
View Detailed Chart

4.679USD

-0.011-0.23%
Market hours ETQuotes delayed by 15 min
6.99MMarket Cap
LossP/E TTM

Evoke Pharma Inc

4.679

-0.011-0.23%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.23%

5 Days

+5.63%

1 Month

+72.03%

6 Months

-2.11%

Year to Date

+5.86%

1 Year

-11.88%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 1 analysts
BUY
Current Rating
18.000
Target Price
283.79%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

173
Total
5
Median
8
Average
Company name
Ratings
Analysts
Evoke Pharma Inc
EVOK
1
Biogen Inc
BIIB
37
Vertex Pharmaceuticals Inc
VRTX
34
Alnylam Pharmaceuticals Inc
ALNY
34
Amgen Inc
AMGN
33
Gilead Sciences Inc
GILD
30
1
2
3
...
35

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Buy
Sell(1)
Neutral(3)
Buy(9)
Indicators
Sell(1)
Neutral(3)
Buy(3)
Indicators
Value
Direction
MACD(12,26,9)
-0.239
Neutral
RSI(14)
56.561
Neutral
STOCH(KDJ)(9,3,3)
44.613
Buy
ATR(14)
0.506
Low Volatility
CCI(14)
-16.064
Neutral
Williams %R
41.664
Buy
TRIX(12,20)
0.847
Sell
StochRSI(14)
100.000
Buy
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
4.096
Buy
MA10
4.306
Buy
MA20
4.620
Buy
MA50
3.696
Buy
MA100
3.264
Buy
MA200
4.028
Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.
Ticker SymbolEVOK
CompanyEvoke Pharma Inc
CEOMr. Matthew J. (Matt) D'Onofrio
Websitehttps://evokepharma.com/
KeyAI